Nasus Pharma is trading 5.69% up at $3.81 after hours, following the announcement that the first patient was enrolled and dosed in its NS003 Phase 1 study.
- NS003 is an intranasal ondansetron formulation for chemotherapy-related and post-operative nausea and vomiting; topline data are expected in Q4 2026.
- The regular-session close was $3.60 on September 29, 2026; after-hours volume was not provided. The release did not explicitly attribute the move to the news.